The rise and fall of endothelin receptor antagonists in congestive heart failure

被引：11
作者：
Handoko, M. L. [1 ,2 ]
de Man, F. S. [2 ,3 ]
Vonk-Noordegraaf, A. [2 ]
机构：
[1] Vrije Univ Amsterdam, Dept Physiol, Med Ctr, Inst Cardiovasc Res, NL-1081 BT Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Dept Pulmonol, Med Ctr, Inst Cardiovasc Res, NL-1081 BT Amsterdam, Netherlands
[3] Univ Paris 11, INSERM, Ctr Chirurg Marie Lannelongue, Unit 999, Le Plessis Robinson, France
来源：
EUROPEAN RESPIRATORY JOURNAL | 2011年 / 37卷 / 03期
关键词：
PULMONARY-HYPERTENSION; BOSENTAN; THERAPY;
D O I：
10.1183/09031936.00145910
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：484 / 485
页数：2
相关论文
共 15 条
[1]   PLASMA ENDOTHELIN CORRELATES WITH THE EXTENT OF PULMONARY-HYPERTENSION IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].
CODY, RJ ;
HAAS, GJ ;
BINKLEY, PF ;
CAPERS, Q ;
KELLEY, R .
CIRCULATION, 1992, 85 (02) :504-509
[2]  
Fraccarollo D, 1997, CIRCULATION, V96, P3963
[3]   Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure [J].
Jiang, B. H. ;
Tardif, J-C. ;
Shi, Y. ;
Dupuis, J. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (03) :578-586
[4]   Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [J].
Kalra, PR ;
Moon, JCC ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (2-3) :195-197
[5]   Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - A multi-center randomized study [J].
Kaluski, Edo ;
Cotter, Gad ;
Leitman, Marina ;
Milo-Cotter, Olga ;
Krakover, Ricardo ;
Kobrin, Isaac ;
Moriconi, Tina ;
Rainisio, Maurizio ;
Caspi, Avraham ;
Reizin, Leonardo ;
Zimlichman, Reuven ;
Vered, Zvi .
CARDIOLOGY, 2008, 109 (04) :273-280
[6]   Role of endogenous endothelin in chronic heart failure - Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling [J].
Mulder, P ;
Richard, V ;
Derumeaux, G ;
Hogie, M ;
Henry, JP ;
Lallemand, F ;
Compagnon, P ;
Mace, B ;
Comoy, E ;
Letac, B ;
Thuillez, C .
CIRCULATION, 1997, 96 (06) :1976-1982
[7]   Update of REACH-1 and MERIT-HF clinical trials in heart failure [J].
Mylona, P ;
Cleland, JGF .
EUROPEAN JOURNAL OF HEART FAILURE, 1999, 1 (02) :197-200
[8]   Endothelin and heart failure [J].
Nambi P. ;
Clozel M. ;
Feuerstein G. .
Heart Failure Reviews, 2001, 6 (4) :335-340
[9]   PLASMA ENDOTHELIN DETERMINATION AS A PROGNOSTIC INDICATOR OF 1-YEAR MORTALITY AFTER ACUTE MYOCARDIAL-INFARCTION [J].
OMLAND, T ;
LIE, RT ;
AAKVAAG, A ;
AARSLAND, T ;
DICKSTEIN, K .
CIRCULATION, 1994, 89 (04) :1573-1579
[10]   PLASMA BIG ENDOTHELIN-1 CONCENTRATIONS IN CONGESTIVE-HEART-FAILURE PATIENTS WITH OR WITHOUT SYSTEMIC HYPERTENSION [J].
PACHER, R ;
BERGLERKLEIN, J ;
GLOBITS, S ;
TEUFELSBAUER, H ;
SCHULLER, M ;
KRAUTER, A ;
OGRIS, E ;
RODLER, S ;
WUTTE, M ;
HARTTER, E .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (15) :1293-1299
12